Thermo Fisher Scientific Inc., In the Matter of

Last Updated:
In the Matter of Thermo Fisher Scientific Inc., a corporation.
FTC Matter/File Number:

131 0134

Docket Number:


Enforcement Type:

Part 2 Consents

Case Summary

Thermo Fisher Scientific Inc. agreed to sell assets to GE Healthcare to settle Federal Trade Commission charges that its proposed $13.6 billion acquisition of Life Technologies Corporation (Life) would likely substantially lessen competition.The FTC complaint alleged that the deal, as it was originally proposed, would have eliminated close competition between Thermo Fisher and Life and substantially increased concentration in the markets for short/small interfering ribonucleic acid (siRNA) reagents, cell culture media, and cell culture sera, enabling the combined firm to raise prices and reduce quality for consumers. The proposed order settling the FTC’s charges requires Thermo Fisher to divest its gene modulation business Dharmacon, which contains the siRNA reagents business, as well as its cell culture media and sera business including the HyClone brand to GE Healthcare, along with all intellectual property and know-how necessary to operate each of the divested businesses.